DDN

DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice[1].

Product Specifications

CAS Number

[118006-14-7]

UNSPSC

12352005

Hazard Statement

H301-H400

Target

Akt; ERK; Insulin Receptor

Related Pathways

MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Metabolic Disease

Smiles

O=C1C(Cl)=C(Cl)C(C2=C1C(OC(C)=O)=CC=C2OC(C)=O)=O

Molecular Formula

C14H8Cl2O6

Molecular Weight

343.12

Precautions

P264-P270-P273-P330-P391-P405-P501

References & Citations

[1]Kunyan He, et al. Identification of a molecular activator for insulin receptor with potent anti-diabetic effects. J Biol Chem. 2011 Oct 28;286 (43) :37379-88.